Abstract: Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of neurodegenerative disorders and diseases mediated by soluble epoxide hydrolase.

Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula I or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of cancer as a monotherapy or a combination therapy with chemotherapeutic agents and/or checkpoint inhibitors.

Abstract: Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of conditions and diseases mediated by soluble epoxide hydrolase.

Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of 1,1?-(dodecane-1,12-diyl)bis(cyclopropane-1-carboxamide), pharmaceutical salts or derivatives thereof, as described herein, to a subject in need thereof. in certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of conditions and diseases mediated by soluble epoxide hydrolase.

Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula I or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula (I) or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula (I) or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: Novel compounds of Formula I are provided: its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein R1 is selected from a group consisting of hydroxy, alkoxy, amine, alkyl, haloalkyl, NHSO2R, or NHCOR wherein R is selected from alkyl or cycloalkyl, NHR? wherein R? is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy; and n1 and n2 are independently selected from 0, 1, and 2. At least one of R3 and R4 and/or R5 and R6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO2. Additionally, when R3 and R4 or R5 and R6 do not form a cyclic ring, then they may be independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl. L1 is a linear aliphatic chain optionally containing from 4 to 16 carbon atoms. The chain may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl.

Abstract: Novel compounds of Formula A1 are provided: its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein R7 is independently selected from a group consisting of hydroxy, alkoxy, alkyl, amine, NHR? wherein R? is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy, NHSO2R or NHCOR, wherein R is selected from alkyl or cycloalkyl. At least one of R3 and R4 and/or R5 and R6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO2. Additionally R3 and R4 or R5 and R6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl. L1 is independently a linear aliphatic chain optionally containing from 6 to 16 carbon-atoms and L1 may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl.

Abstract: The invention is directed to novel compounds of Formula I: as well as its stereoisomers and/or pharmaceutically acceptable salts, for the treatment of diabetes and diabetes associated dyslipidemia.

Abstract: The invention is directed to novel compounds of Formula I: as well as its stereoisomers and/or pharmaceutically acceptable salts, for the treatment of diabetes and diabetes associated dyslipidemia.

Abstract: Methods for the treatment of insulin resistance, diabetes, and/or diabetes associated dyslipidemia by administering niacin and meloxicam are disclosed.

Abstract: A novel method of identifying compounds capable of upregulating Peroxiredoxin activity is disclosed. The method includes providing a sample of cells that express Peroxiredoxin, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of Peroxiredoxin activity within the cell sample after the contacting step. Peroxiredoxin inducers identified by the method and uses therefore to upregulate Peroxiredoxin activity in subjects and to reduce LDL and/or VLDL levels and to prevent or treat atherosclerosis and inflammatory disorders such as arthritis in subjects are also described. The invention also provides a method of treatment of inflammatory and cardiovascular diseases which comprises providing a patient in need of treatment with an effective amount of a composition that increases Peroxiredoxin protein or activity.

Abstract: The present invention is directed to a compounds, methods and compositions for making the compounds and methods of treating a variety of diseases and disease states including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan, comprising the administration of new heterocyclic compounds, particularly substituted pyrimidines.

Abstract: The present invention provides, among other things, new bicyclic heterocyclic compounds, compositions comprising these heterocyclic compounds, methods of making the heterocyclic compounds, and methods of using these heterocyclic compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

Abstract: The present invention provides new heterocyclic compounds, particularly substituted pyridines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan.

Abstract: A novel method of identifying compounds capable of upregulating GATA activity is disclosed. The method includes providing a sample of cells that express GATA, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of GATA activity within the cell sample after the contacting step. GATA inducers identified by the method and uses therefore to upregulate GATA activity in subjects and to prevent or treat atherosclerosis or diabetes in subjects are also described.

Abstract: Methods for the treatment of insulin resistance, diabetes, and/or diabetes associated dyslipidemia by administering niacin and meloxicam are disclosed.